VERU Veru Inc.
Legal ·
Veru, Chairman and CEO Mitchell Steiner and CFO Michele Greco are defendants in a Florida class action. Five derivative suits name seven officers and directors. Veru says it cannot estimate losses.
Clear Future, Inc. sued Veru Inc. in Delaware Superior Court after buying the FC2 female condom business for $18.0 million in cash. Veru is the defendant named in the 10-Q and says it cannot estimate losses.
A Nasdaq letter received August 26, 2025 says Veru has regained compliance with the $1.00 minimum bid price rule and that the matter is closed. Nasdaq first wrote to the company about the bid price on August 29, 2024.
Veru's 1-for-10 reverse stock split took effect at 11:59 p.m. Central time on August 8, 2025, and the stock trades split-adjusted from August 11. The 8-K gives no reason for the split and no pre-split share count.
The sale closed December 30, 2024. Veru expects about $12.5 million in net proceeds after a $4.2 million change of control payment to SWK Funding LLC, which ended a residual royalty agreement.
Veru closed the sale of its FC2 female condom business on December 30, 2024 for $18.0 million in cash. After a $4.2 million change of control payment to SWK Funding and other fees, it estimates about $12.5 million in proceeds.
Veru Inc. is a late clinical stage biopharmaceutical company developing novel medicines for cardiometabolic and inflammatory diseases. Its two late-stage new chemical entities are enobosarm and sabizabulin. Enobosarm is an oral selective androgen receptor modulator (SARM) being developed to make weight reduction by GLP-1 RA drugs more tissue selective for fat loss and preservation of lean mass. The company reports a positive Phase 2b QUALITY study of enobosarm in older patients who are overweight or obese and receiving a GLP-1 RA, and plans a Phase 2b PLATEAU trial in patients with obesity receiving tirzepatide (ZEPBOUND). Sabizabulin is an oral microtubule disruptor that the company is exploring for inflammation in atherosclerotic cardiovascular disease, with a possible small Phase 2 proof-of-concept study in patients with stable coronary artery disease. The company plans to prioritize internal cash and future financing proceeds for enobosarm. Veru sold its FDA-approved FC2 Female Condom on December 30, 2024. The filing describes the company's move from a single-product business to a biopharmaceutical company after its 2016 acquisition of Aspen Park Pharmaceuticals.
| Product or program | What it is | Stage |
|---|---|---|
| Enobosarm | Oral SARM for weight reduction and preservation of lean mass alongside GLP-1 RA therapy | positive Phase 2b QUALITY study; Phase 2b PLATEAU planned |
| Sabizabulin | Oral microtubule disruptor for inflammation in atherosclerotic cardiovascular disease | exploring clinical development; small Phase 2 proof-of-concept study planned |
| Line | FY ended Sep 30, 2025 | FY ended Sep 30, 2024 |
|---|---|---|
| Research and development | $15.6 million | $12.8 million |
| Net income (loss) | -$22.7 million | -$37.8 million |
| Cash from operations | -$30.0 million | -$21.7 million |
| Cash and equivalents | $15.8 million | $24.9 million |
Our latest story on this, dated Aug 12, 2025: "Veru completes 1-for-10 reverse stock split on Nasdaq". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 10, 2026: "Veru faces securities class action and five derivative suits over sabizabulin statements". The story links the filing or release it is based on. Read the story.
Veru Inc. trades under the ticker VERU on NASDAQ.
Veru Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Veru Inc. is 863894. Its filings are on SEC EDGAR.
17,050,320 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-10.
Our directory records Veru Inc. under United States.
Our directory classifies Veru Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Veru Inc. is US92536C2026.
aibio.space lists Veru Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as WI.
Veru Inc. is a late clinical stage biopharmaceutical company developing novel medicines for cardiometabolic and inflammatory diseases. Its two late-stage new chemical entities are enobosarm and sabizabulin.
Enobosarm: Oral SARM for weight reduction and preservation of lean mass alongside GLP-1 RA therapy Stage: positive Phase 2b QUALITY study; Phase 2b PLATEAU planned.
Sabizabulin: Oral microtubule disruptor for inflammation in atherosclerotic cardiovascular disease Stage: exploring clinical development; small Phase 2 proof-of-concept study planned.
Veru Inc. reported a net loss of $22.7 million for the fiscal year ended Sep 30, 2025, and used $30.0 million of cash in operations, per its annual report to the SEC.
Reported a financing. SEC Form 424B5. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported that a debt obligation was accelerated. SEC Form 8-K (Items 1.01,1.02,2.01,2.04,8.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio